Peptide PilotPeptide Pilot

Dose calculator

TB-500 dose calculator

Convert any TB-500 dose into syringe units in real time, pre-filled with a 5 mg / 2 mL example.

Download Peptide PilotiPhone · Free to download

Draw on a U-100 syringe

80.0 units

Volume to draw

0.800 mL

TB-500 is a synthetic fragment of the natural protein Thymosin Beta-4 that people use to support recovery from soft-tissue and tendon injuries. It works by promoting cell migration and new blood-vessel formation at injury sites, which is what allows damaged tissue to rebuild faster. Animal studies show meaningful acceleration of wound and tendon healing; controlled human data is limited. This page covers reconstitution math and how people typically log a loading-then-maintenance schedule.

How the TB-500 dose calculator works

This calculator answers a simple question: given the concentration of the TB-500 solution already in your vial, how many syringe units does today's dose work out to? It is the second half of the reconstitution math — the first half locks in concentration, this one converts any dose mg or mcg into a clean unit count.

The formula is volume in mL equals dose mg divided by concentration mg/mL, then volume times one hundred to get units on a U-100 insulin syringe. With a 2.5 mg/mL TB-500 solution and a 2 mg dose, the draw is 0.80 mL or about 80 units. Type any other dose and the unit count updates in real time — no spreadsheets, no guesswork.

Inputs that genuinely matter: concentration (which only changes when you reconstitute a new vial) and dose mass. Syringe type matters too, but only because U-100 vs U-40 changes the multiplier — almost every modern insulin syringe is U-100, which is why the math defaults to that. Edge cases worth flagging: switching from mcg to mg without checking the input unit, or carrying yesterday's unit count over to a new vial that was reconstituted with a different volume of BAC water.

Most people use this calculator at two moments: when titrating a dose up or down, and when prepping a single dose before injection. The output is meant to be checked against the syringe before drawing — read the markings, confirm the unit count, then draw. The calculator is fast precisely so you can do that check every time without it feeling like a chore.

How TB-500 dosing is tracked

Logs documenting TB-500 administration most often show a subcutaneous cadence of once or twice per week, a pattern consistent with a molecule expected to have a prolonged duration of action. Some experimental designs incorporate an initial loading phase, where administration might occur several times per week for one to four weeks, before transitioning to a less frequent maintenance schedule. Due to the milligram-scale doses, a 1mL or 0.5mL U-100 insulin syringe is typically used to accurately draw the calculated volume from the reconstituted vial. Rotation of injection sites is a standard practice recorded in detailed logs to monitor for any localized skin reactions.

When planned in conjunction with a peptide requiring daily administration, like BPC-157, TB-500 is scheduled on its own rhythm within the week. A tracker might record daily BPC-157 entries while logging TB-500 doses only on Mondays and Thursdays, for example. This separation ensures that each protocol can be monitored independently without complex timing interactions. The precise time of day for a TB-500 dose is often considered less critical than for short-acting peptides, as the goal is to maintain a stable systemic concentration over many days rather than targeting a narrow post-injection activity window.

TB-500 mechanism in plain English

The proposed mechanism of TB-500 is directly inherited from its parent protein, Thymosin Beta-4, which functions as the primary G-actin-sequestering molecule inside cells. G-actin (globular actin) monomers are the fundamental building blocks of F-actin (filamentous actin), which forms the microfilaments of the dynamic cellular cytoskeleton. By binding to G-actin with a 1:1 stoichiometry, Thymosin Beta-4 controls the available pool of monomers and thus modulates the rate and spatial dynamics of actin polymerization. This intricate process of cytoskeletal rearrangement is fundamental to a cell's ability to change shape, exert force, move, and divide, making it a critical control point for cell motility and migration.

This specific actin-modulating activity is the molecular basis for the effects observed in research studies examining wound closure, inflammation, and tissue protection. For a cell to migrate—such as a keratinocyte moving into a wound bed, a fibroblast depositing extracellular matrix, or an endothelial cell forming a new blood vessel—it must be able to rapidly assemble and disassemble its actin cytoskeleton to crawl and navigate its environment. By influencing this core cellular machinery, TB-500 is studied for its potential to support these actin-dependent processes. This mechanism is biochemically distinct from pathways targeted by other peptides, such as those that directly stimulate angiogenic growth factors or activate specific G-protein coupled receptors, explaining its unique profile in research.

Common TB-500 dose mistakes

  • Assuming the same unit measurement as BPC-157 when they are stacked, leading to a significant under-dose of TB-500 due to its milligram-scale dosing.
  • Entering a 2.5 mg dose into a calculator field that defaults to micrograms (mcg), resulting in a miscalculation of several orders of magnitude.
  • Allowing a twice-weekly schedule to drift by a day each week, altering the dosing interval from a 3-day/4-day pattern to a 4-day/5-day pattern over time.
  • Using only 1 mL of diluent for a 10 mg vial and finding the resulting solution too concentrated to measure small dose adjustments precisely on a U-100 syringe.
  • Failing to log the 'loading' phase parameters separately from the 'maintenance' phase, making it difficult to analyze the distinct periods of the protocol later.

Frequently asked questions about TB-500 dose

Why are TB-500 doses measured in milligrams (mg) while many others are in micrograms (mcg)?
The dosage scale is related to the peptide's molecular structure and the concentrations studied in research literature. TB-500 is a fragment of a larger, naturally abundant protein, and the quantities examined for biological activity are correspondingly higher than those for smaller synthetic peptides that act on highly sensitive receptors. This difference in magnitude necessitates using milligrams as the unit of measurement for accurate planning, calculation, and tracking.
If I use a 5 mg vial and 2 mL of diluent, how many units do I draw for a 2 mg dose?
With a 5 mg vial reconstituted with 2 mL of bacteriostatic water, the concentration becomes 2.5 mg per mL. To calculate a 2 mg dose, you would need 0.8 mL of the solution. On a U-100 insulin syringe, where 100 units equal 1 mL, 0.8 mL is equal to 80 units. Using a dose calculator is the most reliable way to convert your desired milligram dose into the correct syringe units.
What is the rationale behind a twice-weekly administration schedule?
The less frequent administration schedule, such as twice per week, documented in research logs for TB-500 is generally associated with a longer biological half-life compared to peptides requiring daily or more frequent dosing. This allows for sustained systemic levels to be maintained without the logistic complexity of daily administration. The specific interval (e.g., Monday/Thursday) is chosen to keep peptide concentrations relatively consistent throughout the week.
How does TB-500's mechanism differ from that proposed for BPC-157?
Research suggests they operate through different primary pathways. TB-500's proposed mechanism involves modulating actin dynamics, a fundamental intracellular process for cell structure and migration. In contrast, BPC-157 is primarily studied for its influence on the nitric oxide (NO) system and its effects on angiogenesis (the formation of new blood vessels), largely extracellular and signaling-based activities. Because these mechanisms are distinct, they are often studied in combination to observe their potentially complementary roles.
Is a 'loading phase' documented in research protocols?
Some logs and research reports document a 'loading phase,' characterized by more frequent or higher doses for an initial period, followed by a lower-dose 'maintenance phase.' The theory is to more rapidly elevate systemic concentrations to a steady state. However, other protocols begin directly with a maintenance-style cadence. Tracking logs show both approaches being used, and the decision to use a loading phase is a key variable to document when planning and reviewing a research cycle.
Can I pre-load syringes with TB-500 for a week?
Pre-loading syringes introduces additional stability variables, primarily concerning the interaction of the reconstituted peptide with the syringe materials over time. The stability of most peptides is best characterized in sterile glass vials, not in plastic syringes where factors like surface adsorption and interaction with the rubber plunger are unknown. For this reason, the standard practice documented is to draw each dose from the refrigerated vial immediately before administration to ensure consistency and minimize potential degradation.

Related on Peptide Pilot

Log every TB-500 dose in the app

Download on the App Store
Get the App